Pinnacle Wealth Planning Services Inc. Buys Shares of 777 Insulet Corporation $PODD

Pinnacle Wealth Planning Services Inc. bought a new stake in shares of Insulet Corporation (NASDAQ:PODD) during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor bought 777 shares of the medical instruments supplier’s stock, valued at approximately $244,000.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. American Century Companies Inc. boosted its holdings in Insulet by 34.8% during the 1st quarter. American Century Companies Inc. now owns 1,152,606 shares of the medical instruments supplier’s stock valued at $302,686,000 after acquiring an additional 297,734 shares during the period. Nuveen LLC purchased a new stake in Insulet in the first quarter worth $74,163,000. Kayne Anderson Rudnick Investment Management LLC lifted its position in shares of Insulet by 1,316.5% during the first quarter. Kayne Anderson Rudnick Investment Management LLC now owns 193,511 shares of the medical instruments supplier’s stock worth $50,818,000 after purchasing an additional 179,850 shares during the last quarter. Vanguard Group Inc. lifted its position in shares of Insulet by 2.1% during the first quarter. Vanguard Group Inc. now owns 8,668,952 shares of the medical instruments supplier’s stock worth $2,276,553,000 after purchasing an additional 178,976 shares during the last quarter. Finally, AustralianSuper Pty Ltd boosted its stake in shares of Insulet by 487.5% during the second quarter. AustralianSuper Pty Ltd now owns 205,168 shares of the medical instruments supplier’s stock valued at $64,460,000 after purchasing an additional 170,247 shares during the period.

Wall Street Analyst Weigh In

A number of equities analysts have recently commented on the stock. Raymond James Financial raised their target price on shares of Insulet from $360.00 to $366.00 and gave the stock an “outperform” rating in a research report on Friday, November 7th. JPMorgan Chase & Co. increased their price objective on Insulet from $340.00 to $415.00 and gave the stock an “overweight” rating in a research note on Friday, September 12th. Piper Sandler raised their price objective on Insulet from $320.00 to $360.00 and gave the stock an “overweight” rating in a report on Tuesday, September 16th. UBS Group raised Insulet from a “neutral” rating to a “buy” rating and lifted their target price for the company from $355.00 to $400.00 in a research report on Wednesday. Finally, Morgan Stanley reiterated an “overweight” rating on shares of Insulet in a report on Thursday, August 7th. One research analyst has rated the stock with a Strong Buy rating, twenty have issued a Buy rating and two have issued a Hold rating to the stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $376.35.

Insider Activity

In other Insulet news, SVP Laetitia Cousin sold 797 shares of the business’s stock in a transaction dated Monday, September 8th. The shares were sold at an average price of $348.81, for a total value of $278,001.57. Following the completion of the transaction, the senior vice president directly owned 3,890 shares in the company, valued at approximately $1,356,870.90. The trade was a 17.00% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, SVP Prem Singh sold 687 shares of the stock in a transaction dated Monday, September 8th. The shares were sold at an average price of $347.49, for a total transaction of $238,725.63. Following the sale, the senior vice president directly owned 3,456 shares of the company’s stock, valued at approximately $1,200,925.44. The trade was a 16.58% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. 0.39% of the stock is owned by insiders.

Insulet Stock Performance

Shares of PODD stock opened at $346.36 on Thursday. The firm has a market cap of $24.37 billion, a price-to-earnings ratio of 105.28, a PEG ratio of 2.64 and a beta of 1.39. Insulet Corporation has a 52-week low of $230.05 and a 52-week high of $353.50. The company has a quick ratio of 1.81, a current ratio of 2.26 and a debt-to-equity ratio of 0.64. The company’s 50 day moving average is $322.93 and its 200 day moving average is $314.19.

Insulet (NASDAQ:PODD) last announced its earnings results on Thursday, November 6th. The medical instruments supplier reported $1.24 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.13 by $0.11. Insulet had a return on equity of 23.78% and a net margin of 10.01%.The business had revenue of $521.70 million for the quarter, compared to analysts’ expectations of $678.70 million. During the same quarter last year, the firm earned $1.08 EPS. The business’s revenue for the quarter was up 29.9% on a year-over-year basis. Insulet has set its FY 2025 guidance at EPS. Q4 2025 guidance at EPS. On average, sell-side analysts anticipate that Insulet Corporation will post 3.92 EPS for the current fiscal year.

Insulet Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.